HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Astragaloside IV Blunts Epithelial-Mesenchymal Transition and G2/M Arrest to Alleviate Renal Fibrosis via Regulating ALDH2-Mediated Autophagy.

Abstract
Previous studies show that astragaloside IV (ASIV) has anti-renal fibrosis effects. However, its mechanism remains elusive. In this study, we investigated the anti-fibrosis mechanisms of ASIV on chronic kidney disease (CKD) in vivo and in vitro. A CKD model was induced in rats with adenine (200 mg/kg/d, i.g.), and an in vitro renal fibrosis model was induced in human kidney-2 (HK-2) cells treated with TGF-β1. We revealed that ASIV significantly alleviated renal fibrosis by suppressing the expressions of epithelial-mesenchymal transition (EMT)-related proteins, including fibronectin, vimentin, and alpha-smooth muscle actin (α-SMA), and G2/M arrest-related proteins, including phosphorylated p53 (p-p53), p21, phosphorylated histone H3 (p-H3), and Ki67 in both of the in vivo and in vitro models. Transcriptomic analysis and subsequent validation showed that ASIV rescued ALDH2 expression and inhibited AKT/mTOR-mediated autophagy. Furthermore, in ALDH2-knockdown HK-2 cells, ASIV failed to inhibit AKT/mTOR-mediated autophagy and could not blunt EMT and G2/M arrest. In addition, we further demonstrated that rapamycin, an autophagy inducer, reversed the treatment of ASIV by promoting autophagy in TGF-β1-treated HK-2 cells. A dual-luciferase report assay indicated that ASIV enhanced the transcriptional activity of the ALDH2 promoter. In addition, a further molecular docking analysis showed the potential interaction of ALDH2 and ASIV. Collectively, our data indicate that ALDH2-mediated autophagy may be a novel target in treating renal fibrosis in CKD models, and ASIV may be an effective targeted drug for ALDH2, which illuminate a new insight into the treatment of renal fibrosis and provide new evidence of pharmacology to elucidate the anti-fibrosis mechanism of ASIV in treating renal fibrosis.
AuthorsDong Li, Yuzhe Liu, Quancao Zhan, Yan Zeng, Ze Peng, Qifeng He, Qi Tan, Wenfu Cao, Shang Wang, Jianwei Wang
JournalCells (Cells) Vol. 12 Issue 13 (Jul 04 2023) ISSN: 2073-4409 [Electronic] Switzerland
PMID37443810 (Publication Type: Journal Article)
Chemical References
  • Transforming Growth Factor beta1
  • astragaloside A
  • Proto-Oncogene Proteins c-akt
  • Tumor Suppressor Protein p53
  • TOR Serine-Threonine Kinases
  • ALDH2 protein, human
  • Aldehyde Dehydrogenase, Mitochondrial
Topics
  • Rats
  • Humans
  • Animals
  • Transforming Growth Factor beta1 (metabolism)
  • Epithelial-Mesenchymal Transition
  • Proto-Oncogene Proteins c-akt (metabolism)
  • Apoptosis
  • Molecular Docking Simulation
  • Tumor Suppressor Protein p53
  • Cell Line, Tumor
  • G2 Phase Cell Cycle Checkpoints
  • Fibrosis
  • Renal Insufficiency, Chronic
  • TOR Serine-Threonine Kinases (metabolism)
  • Autophagy
  • Aldehyde Dehydrogenase, Mitochondrial (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: